|
HS Code |
401920 |
| Generic Name | Nicardipine |
| Brand Names | Cardene |
| Drug Class | Calcium channel blocker |
| Therapeutic Use | Antihypertensive, antianginal |
| Route Of Administration | Oral, intravenous |
| Molecular Formula | C26H29N3O6 |
| Mechanism Of Action | Inhibits calcium ion influx into vascular smooth muscle and myocardium |
| Common Side Effects | Headache, flushing, peripheral edema |
| Contraindications | Severe aortic stenosis, hypersensitivity |
| Half Life | 8 hours |
| Pregnancy Category | Category C (US FDA) |
| Protein Binding | 95% |
| Metabolism | Hepatic |
| Excretion | Urine (major), feces (minor) |
| Onset Of Action | 5-15 minutes (IV) |
As an accredited Nicardipine factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | The packaging for Nicardipine typically includes a 10 mg/10 mL clear glass vial, labeled with dosage, expiration date, and storage instructions. |
| Shipping | Nicardipine is shipped as a regulated pharmaceutical, typically in sealed containers compliant with safety guidelines. It requires secure packaging to prevent contamination and breakage, and is often protected from light and moisture. Depending on the formulation, temperature control may be necessary. Shipping must comply with all local, national, and international regulations. |
| Storage | Nicardipine should be stored at **20°C to 25°C (68°F to 77°F)**, protected from light and moisture. Keep it in a tightly closed container and away from incompatible substances. Store in a secure area out of reach of children. Do not freeze nicardipine injection solutions, and protect them from excessive heat to maintain stability and effectiveness. |
Applications of Nicardipine in Industrial ManufacturingNicardipine is widely adopted by pharmaceutical and fine chemical manufacturers as a reference-grade calcium channel blocker intermediate. Produced at GMP-compliant facilities, it plays a critical role in specialty medication formulations and analytical systems, extending across hospital injectable preparations, oral solid dose products, and regulated impurity reference standard generation. As an original manufacturer, we focus on application pathways with established industry requirements, supporting licensed formulators globally with consistently compliant raw material for high-value end-use scenarios. 1. Hospital Injectable Antihypertensive MedicationsPharmaceutical facilities use this active ingredient to formulate sterile intravenous antihypertensive drugs deployed in emergency and perioperative care. The material enters solution preparation stages requiring continuous in-process quality controls to achieve high purity and physicochemical stability, especially critical for parenteral routes. Each batch undergoes validation against pharmacopeia monographs and regulatory submissions, guiding allowable excipient and solvent interactions. Hospital applications set strict impurity profile and particulate content limits, requiring ongoing process capability monitoring aligned to compounding line controls. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
2. Oral Solid Dosage Form (Tablet/Capsule) APIsContract and in-house pharmaceutical production sites manufacture solid dosage antihypertensive medications using this active pharmaceutical ingredient as the core of their blend. Granulation, blending, and compaction processes require material with consistent particle size and flow properties to ensure uniform distribution within multi-excipient tablets and capsules. Release testing for dissolution rate, content uniformity, and impurity detection uses both compendial and in-house analytical methods. Only pharmaceutical-grade lots meeting precise dissolution and stability criteria qualify for integration into multi-step blending, compression, and film-coating procedures. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
3. Pharmaceutical Reference Standards and Impurity ProfilingReference laboratories, pharmaceutical QC, and API manufacturers require highly pure Nicardipine as secondary standards and for impurity profiling during development and batch release. Certified and traceable batches support identity confirmation and method calibration when evaluating raw materials, in-process samples, and finished products. Advanced purification, batch-to-batch consistency, trace documentation, and multi-point chromatographic validation ensure suitability for analytical calibration and regulatory audit trails. These materials serve as a benchmark for stability-indicating assay development and impurity threshold quantification. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
4. Pre-Clinical Formulation Development for Drug DiscoveryCROs, biotech R&D departments, and formulation scientists use research-grade Nicardipine in pre-clinical development pipelines, including toxicology, PK/PD studies, and initial dosage form screening. Small-scale formulation and analytical teams require batch-to-batch consistency in purity and polymorphic form to assess new solid and liquid delivery systems prior to upscaling. Production lots must meet GLP documentation and provide full traceability for archived sample integrity, enabling confident assessment of test article stability and behavior under simulated manufacturing conditions. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
|
Competitive Nicardipine prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
In our facilities, each batch of Nicardipine gets more than a checklist. We have spent decades refining synthesis and purification steps, and every reactor run adds to our hands-on skill. Nicardipine, as a calcium channel blocker, starts as a demand from the cardiovascular field, but its production challenges pull together organic chemistry, separation science, and strict control over impurities.
We have seen requests range from grams for research to multi-ton commercial campaigns. Our Nicardipine hydrochloride comes as a crystalline powder, often demanded at the highest available purity. During crystallization, solvent choice and seeding make a visible difference in particle size and purity, which means our operators run in-lab checks before every packaging run. In pharmaceuticals, those small checks prevent downstream headaches and late-stage rejections, so we take this part as seriously as regulatory registration.
Buyers ask us about our models and specifications, often expecting a simple answer. Our main product line covers Nicardipine hydrochloride with purity above 99.5%, meeting or exceeding compendial standards. Moisture content, heavy metal levels, residual solvents—these aren’t back-office numbers. Every client volume has its own release specs, and we treat those as minimums, not targets.
Analytical chemists on our team run HPLC checks on every lot, confirming the API profile, checking related substances, and making sure nothing exceeds identified limits. Impurity A is a routine concern for the industry at large, and our history of deep cleaning between campaigns lets us keep it below 0.1% even at larger scales. We rarely face sudden spikes in unknowns, because each batch report ties into production data, not gut feel or generic batch sheets copied from somewhere else.
Our Nicardipine typically comes as a white to off-white powder. We do not add anti-caking agents or masking scents. Any detected trace odor means it doesn’t ship. The crystalline form sets the foundation for tablet and injectable manufacturers, who depend on solubility and solution clarity during formulation. We routinely check pH in solution, and update our drying protocols with every block of customer feedback. No batch gets released until it stands up to extended stability observations—any product that shifts color or decomposes under stress goes back for investigation.
Seeing inside the manufacturing process, you notice how raw material sourcing and reaction control make or break a batch. Each synthetic sequence includes Grignard addition, cyclization, and multiple purification cycles. We keep records of solvent lots and analyze trace impurities, not just at the final step but across intermediates. That way, if any anomaly pops up—a shift in melting point, minor yield drop, or odd peak in HPLC spectra—we can track down the source before scale-up turns a minor error into major waste.
Temperature control during the Grignard step decides not only the main product yield but how much byproduct we get. Our teams manually monitor key distillations and adjust at each scale. Crystallization remains more art than algorithm. Over time, our shift supervisors—some with decades in the plant—lend an eye to the fine details, such as crystal habit under the scope or solution clarity after washing.
For years, we have stuck with incremental process improvements: better filtration systems, more precise solvent recovery, automated batch records linked to real-time sensor data. Each of these shifts brings direct gains in cleaner product and reduced environmental load. No batch leaves the plant without meeting all cleanroom particulate standards and compliance with environmental discharges.
We don’t outsource the steps that matter. Solvents, reagents, and key starting materials come only from vetted suppliers who pass our own audit. We ask for full traceability—and because of that, we catch problems before they amplify. Our people inspect, measure, and re-measure. The result is a powder that matches the expected profile, every shipment.
Our experience as a primary producer lands us in close conversations with formulation teams and regulatory specialists at pharmaceutical companies. Nicardipine serves as an API in antihypertensive medications, and injectable preparations allow rapid titration in critical care. Hospitals value predictable dissolution and stability, so we spend effort maintaining uniformity in particle size distribution between lots.
Through direct technical support, we field questions about solution clarity, flowability during tableting, and compatibility with excipients. A minor shift in powder morphology, often overlooked in some production setups, leads to real-world formulation issues like capping or slow dissolution. By owning the process and listening to formulating pharmacists, we bridge the gap from synthetic lab to finished pharmaceutical product.
We collaborated with end-users who faced injectability problems—precipitation in small-bore lines or slow filtering during batch compounding. Our feedback loop traced these issues to subtle changes in recrystallization temperature, a tweak we implemented to narrow the batch-to-batch variation. In this way, every cycle through our line leads to improved product that fits into real-world workflows.
Over the years, the pharmaceutical API space has filled up with intermediaries, repackagers, and traders. Being a direct manufacturer, our main distinction comes from daily control over each process variable and decades of accumulated experience in Nicardipine chemistry. Whether walking the plant floor or analyzing GC/MS plots in the lab, our people live and breathe the product.
Some suppliers take purity at face value, relying solely on third-party results or broad commercial specs. We embed analytical processes from raw material checks to finished lots, and every release comes from our in-house QC labs. Out-of-spec batches never go past our wall; we deliver only lots that have passed the full panel of tests demanded by major pharmacopoeias and our multinational clients.
Physical properties matter as much as chemical purity. Tablet manufacturers rely on our product to flow well, stay free from large aggregates, and dissolve at a predictable rate. Each process tweak—improved drying, better milling, or more refined sieving—directly affects formulation results on the client’s side. Our willingness to collaborate on custom particle size specifications, for example, sets us apart from large-volume resellers or brokers who lack control over the production chain and can only offer standard lots.
We take pride in batch-to-batch reproducibility. No unexplained spikes in impurity levels, no batch blending to mask subpar lots. Document trails, in-process monitoring, and prompt correction of deviations lead to consistent results. Any buyer who has dealt with unstable sources—large material swings, off-odors, unexpected agglomeration—knows the value in dealing with an actual producer who can fix root-cause issues directly.
Our technical support team doesn’t end the relationship at delivery. We routinely help pharmaceutical clients through registration dossiers, stability testing, and compatibility studies. If a new regulatory question arises, or a different packaging solution is needed, our process chemists and logistics teams handle it internally and adjust future shipments accordingly.
The global regulatory environment grows stricter every year, and chemical plants can’t treat compliance as an afterthought. Our own documentation comes from lived experience: site inspections, onsite audits, and near-real-time process monitoring. Auditors from health authorities frequently walk through our facilities and review process logs, batch protocols, and data integrity systems in detail.
Routine GMP audits by multinational clients push us to keep every production and analytical record in order. Calibration, training, change control—these aren’t background procedures but daily work. Every step in our Nicardipine line, from tank cleaning to vial labeling, gets signed by responsible personnel and verified by QC. Any deviation, however minor, triggers investigation. This direct feedback loop is why our plant’s rejection rates for out-of-spec material remain among the lowest in our region.
The rise of data traceability has made our jobs more visible, not less. For Nicardipine, regulators request everything from impurity profiling to supply chain traceability. Our documentation systems link each raw material to the final lot, and digital logs let us answer client or regulatory queries with real evidence, not estimates or after-the-fact summaries.
Being able to supply US, EU, and Asian markets requires a deep understanding of local regulations. We adapt our batch documentation, change notification systems, and risk assessments to the standards for each client jurisdiction. Frequent changes in regulatory expectations—like limits on nitrosamines or updates in USP/EP monographs—never catch us off guard. We respond quickly, because missing a new impurity threshold or documentation format could jeopardize client licenses or, more importantly, patient safety.
Manufacturing is more than chemistry—it’s an environmental and workplace safety balancing act. During Nicardipine production, our plant invests in closed-loop solvent systems and advanced emissions controls. Recovery units for acetone and other solvents let us reduce both raw material demand and environmental footprint.
Worker safety underpins every step. Hazardous reagents and pressurized vessels require training, not just signage. Our teams operate in fully contained gear, and emergency shower and ventilation systems get regular test runs. Incidents get logged transparently, and the lessons from every near miss make their way into future protocols.
Accredited environmental engineers monitor both liquid and vapor-phase emissions. For years, local authorities and client auditors have reviewed our compliance with discharge and waste-recycling limits. Our waste streams—filter cakes, wash waters, and solvent residues—never get mixed or diluted. Detailed batch logbooks mean any environmental concern traces directly back to a production record, and that keeps our entire team sharp.
We also invest in long-term impacts. Over time, our solvent recovery rates improved twenty percent. Each incremental improvement—better distillation columns, updated sensor systems, closed material transfer—adds up. For our customers, this translates to a product with a lower environmental burden and a transparent origin story.
From our vantage point, the world of API supply often looks simple from the outside—buy, sell, ship. Yet direct engagement with every lot exposes why real, repeatable quality takes years to achieve. For Nicardipine, subtle details make the difference: a slightly slower filtration can eliminate a persistent impurity; a measured tweak to recrystallization protocol ensures powder stability after months on the shelf. No software or offsite testing replaces the trained instincts of packaging and analytical teams who see hundreds of batches pass through each year.
Production scheduling and plant downtime affect more than shipment dates. Overbooking, rushing a crystallization, or swapping a raw material before vetting sets up real risks to finished product quality. We keep our order books realistic and run campaign production only with fully cleared materials and validated protocols. This approach leads to slower, surer growth but builds strong track records.
When pandemic-era supply disruptions hit, our established buffer stocks and tight supplier relationships meant we kept shipping while other platforms delayed or canceled. We keep raw material inventories on hand, diversify our critical reagent suppliers, and maintain active risk registers. Direct manufacturing gives us this control—resellers don’t see the pinch points until a shipment fails, but in the plant, each hazard gets an advanced response.
Our end-users know that open communication solves problems fast. A recall or production delay is not a loss of face—it’s an opportunity to present the real facts to customers and regulators, correct the process, and restore confidence. Direct relationships with formulation chemists and regulatory teams mean we stay ahead of problems before they grow.
Our relationships with pharmaceutical developers often start during scale-up trials. Some manufacturers run into issues with filterability, solution stability, or API-excipient compatibility. We approach these not as “special requests” but as the real test of manufacturer value. By working with the actual production data, we can tweak synthesis or purification steps for unique formulations—changing the particle size cut, water content, or packaging routine to match a new clinical application.
On one project, a client’s injectable failed to pass clarity tests under stress. By reviewing batch data logs and running parallel small-scale crystallizations, our team found that a process parameter—solvent switch timing—affected the trace impurity partitioning. Fixing this led to clear solutions and successful downstream vial filling.
For solid oral forms, some developers request tighter bulk density controls or modified milling to support new tableting processes. Instead of sending out standard COAs and calling it a day, we bring together our formulation experts and process techs to test alternative blending, granulation, or coating procedures. That way, clients get ongoing access to the people who know the chemistry in detail, not a call center or generic contact.
By staying close to the technical challenges, we keep pushing process improvements. Small feedback loops from the end-users lead to big quality gains in ongoing production. As new delivery systems and regulatory standards arise, we meet those challenges in the plant and laboratory, not just through paper updates.
Being a manufacturer, we control packaging, shipment timing, and documentation workflows. Lead times depend on campaign scheduling and global shipping trends, not middleman promises. Our logistics teams prepare documentation for each major health authority, and we track shipments until confirmed delivery.
Major disruptions, like weather events or customs delays, get handled directly by our staff who know the shipment contents, temp monitor requirements, and legal documentation inside out. Our warehouses package under controlled humidity, and each outgoing lot receives tamper-evident seals and custom labeling as per destination requirements.
Our global clients face different customs and packaging rules, so our logistics and compliance teams keep up with current requirements, from carton markings to documentation forms. By managing every detail ourselves, we keep shipments on schedule and in compliance, with full traceability back to production batch records.
Having supplied Nicardipine for years, we understand the difference it makes to control every part of the process. Each order goes deeper than a simple sale—our plant teams and client service chemists put their names and expertise behind every batch, every document, every technical support case.
Our approach builds confidence with clients and regulatory authorities because problems can be traced, improvements have immediate impact, and everything starts with people who know the product inside and out. Whether you work in formulation R&D, production, or regulatory affairs, our perspective as a direct manufacturer means your questions get clear, experienced answers—and every solution links back to someone who knows both the chemistry and the stakes of each order.